

INTEGRA LIFESCIENCES HOLDINGS CORP

Form 8-K

June 14, 2007

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549  
FORM 8-K  
CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): June 12, 2007  
**INTEGRA LIFESCIENCES HOLDINGS CORPORATION**  
(Exact Name of Registrant as Specified in its Charter)

**Delaware**  
(State or Other  
Jurisdiction  
of Incorporation)

**0-26224**  
(Commission  
File Number)

**51-0317849**  
(IRS Employer  
Identification No.)

**311 Enterprise Drive**  
**Plainsboro, NJ**  
(Address of Principal Executive Offices)

**08536**  
(Zip Code)

Registrant's telephone number, including area code: **(609) 275-0500**  
(Former Name or Former Address, if Changed Since Last Report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 7.01 Regulation FD Disclosure**

On June 12, 2007, Stuart M. Essig entered into a Stock Sale Plan pursuant to Rule 10b5-1 of the Securities Exchange Act of 1934, as amended (the Exchange Act ). Under Rule 10b5-1, corporate insiders may adopt a prearranged plan or contract for the sale of company securities under specified conditions and times.

Mr. Essig, President and Chief Executive Officer and a director of Integra LifeSciences Holdings Corporation (the Company ), has authorized Piper Jaffray & Co. to sell on his behalf up to 223,163 shares of the Company's Common Stock at specified increasing price levels ranging from \$52.00 per share to \$64.00 per share. The sales should occur before December 31, 2008. Shares of Common Stock to be sold under the Stock Sale Plan are owned by Mr. Essig. The Stock Sale Plan terminates when the number of shares of Common Stock sold pursuant to the plan total 223,163 shares or when earlier terminated in accordance with the Stock Sale Plan.

Except as may be required by law, the Company does not undertake to report future plans by officers or directors of the Company nor to report modifications, terminations, transactions or other activities under such plans.

The information in this Current Report on Form 8-K is furnished pursuant to Item 7 and shall not be deemed to be filed for the purpose of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INTEGRA LIFESCIENCES HOLDINGS  
CORPORATION

Date: June 13, 2007

By: /s/ Stuart M. Essig  
Stuart M. Essig  
Title: President and Chief Executive  
Officer